Stratification of patients with bladder cancer for cystoscopic surveillance

Lead Participant: CYTOSYSTEMS LIMITED

Abstract

Cytosystems Ltd has been researching the potential to assess bladder cancer by means of a urine test.

Its research over a 6 year period has led to a greater understanding of the challenges of collecting and

processing urine samples and detecting the presence of cancerous cells. This project will allow the urine

collection and processing to be easily carried out in the clinic or general practice followed by an

automated system to analyse the cancerous cells, potentially avoiding the need for bladder cancer

patients to undergo uncomfortable cystocopy during routine surveillance after treatment.

Bladder cancer is the 4th most common cancer in men and 7th in women and is one of the most

expensive to manage, this new test should significantly reduce costs and deliver more patient comnfort

without compromising patient safety.

Lead Participant

Project Cost

Grant Offer

 

Participant

CYTOSYSTEMS LIMITED

Publications

10 25 50